FishtownFish wrapped around the rod of AsclepiusMedicine
Philadelphia Primary Care
How It Works
What People Say
Patient reviews across 6 platforms
Articles
Symptoms
What your body is telling you
Treatments
Protocols, prescriptions, therapies
Longevity
Medicine 3.0 strategies
Heart Health & Risk
Protect your heart & vessels
Metabolism
Insulin, blood sugar, weight
Hormones
TRT, thyroid, menopause, andropause
Performance
VO2 max, muscle, sleep, gut
Playbooks
Step-by-step frameworks
About
Meet Dr. Ash
Your Physician
GERO·SPAN
Our Clinical Framework
FAQ
Common Questions
Book a Free Call
How We Review Genetic Results
Fishtown Medicine•5 min read

How We Review Genetic Results

On This Page
  • What kind of genetic data can you send us?
  • What is our interpretation framework?
  • How does genetics change your care plan?
  • Guidance from the clinic
  • Actionable Steps for Genetic Agency
  • Key Takeaways
  • Common Questions
  • Can you actually use my 23andMe raw data?
  • What is the difference between consumer and clinical genetic testing?
  • Do I need a referral to upload my data?
  • Will my genetic data be shared with insurance?
  • How long does the review take?
  • Is whole genome sequencing better than 23andMe?
  • What can pharmacogenomic testing tell me?
  • Will the consult tell me if I have cancer genes?
  • Deep Questions
  • What is a polygenic risk score and how do you use it?
  • How does APOE genotype change cardiovascular and dementia care?
  • What is the role of MTHFR variants in real clinical care?
  • How do you handle the COMT "warrior vs. worrier" gene?
  • What is the difference between BRCA testing and a polygenic breast cancer risk score?
  • How does pharmacogenomics affect SSRI selection?
  • What is GINA and what does it protect?
  • How do you interpret a "variant of uncertain significance" (VUS)?
  • Can lifestyle change override a high-risk genetic profile?
  • How does Fishtown Medicine handle direct-to-consumer pharmacogenomic kits?
  • What is the future of polygenic embryo screening?
  • Why does Fishtown Medicine still emphasize family history alongside genetics?
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR · 30-second take

We review genetic data from consumer panels (23andMe, Ancestry) and clinical panels (Invitae, Color, Nucleus) by translating raw variants into pathway-based action: nutrient needs, drug metabolism, cardiovascular risk, and earlier screening timelines. The goal is precision strategy, not labels. Genetics loads the gun. Lifestyle pulls the trigger.

How Fishtown Medicine Reviews Genetic Results

Your genetics are the blueprint of your health, not your destiny. At Fishtown Medicine, we take your raw data from consumer companies like 23andMe or Ancestry, or from clinical panels like Invitae, Color, or Nucleus, and translate them into a high-leverage personalized care plan. We do not just look for "bad genes." We look for opportunities to optimize nutrition, medication choice, screening timelines, and lifestyle around your unique biology.

What kind of genetic data can you send us?

You can send us several kinds of genetic data, and we can work with most of them:
  1. Raw DNA data: If you have used 23andMe or Ancestry, you can download your raw .txt file and we run it through clinical-grade analysis tools.
  2. Clinical panels: Reports from companies like Invitae or Color used for cancer screening or familial hypercholesterolemia.
  3. Whole genome sequencing: A 30x WGS report from Nucleus or Nebula covers 100 percent of your DNA.
  4. Specialized panels: Pharmacogenomic tests, MTHFR-specific reports, APOE status, and BRCA testing.
How to share: Upload files directly to your secure portal in the Ultralight app. We never email genetic data.

What is our interpretation framework?

Our interpretation framework uses pathway analysis instead of single-gene labeling. We do not crown you "the MTHFR patient" or "the APOE4 patient." We ask: where does your biology need extra support?
  • Metabolic pathway: Genetic tendencies toward insulin resistance, high triglycerides, or fatty liver.
  • Detoxification pathway: How well your body handles oxidative stress, alcohol, and environmental exposures.
  • Cardiovascular pathway: Markers like Lp(a) and familial hypercholesterolemia variants that standard labs often miss.
  • Longevity pathway: APOE status, polygenic risk scores for neurodegeneration, and protective strategies you can deploy today.
  • Pharmacogenomics: How fast or slow you metabolize specific drug families (CYP2D6, CYP2C19, CYP3A4).

How does genetics change your care plan?

Genetics changes your care plan by replacing generalized advice with precision action. A few real examples:
  • Nutrient precision: A specific MTHFR variant may push us to use methylated B-vitamins instead of standard ones.
  • Medication safety: CYP2D6 status changes the safe dose of antidepressants, opioids, and beta-blockers.
  • Screening timelines: A high polygenic risk score for breast or colon cancer can move your preventive imaging timelines up by a decade.
  • Cardiovascular targets: APOE4 carriers often need stricter ApoB and saturated-fat targets, since the gene amplifies risk from both.
  • Hormone strategy: Variants in COMT and aromatase shape how we approach testosterone, estrogen, and progesterone optimization.

Guidance from the clinic

Dr. Ash
"Your genes code for proteins, but your environment chooses which proteins are active. I tell my patients: genetics loads the gun, but lifestyle pulls the trigger. By knowing what is loaded, we can design an environment where those triggers never get pulled. This is not about fear. It is about the ultimate form of clinical agency."

Actionable Steps for Genetic Agency

Equip your biology.
  1. Download your raw data: Log into your consumer DNA account and download the raw data file today.
  2. Upload to Ultralight: Send the file as a secure attachment in the app.
  3. Schedule a deep-dive review: We typically need 7 to 10 days to process the data through our pathway models before a full consult.
  4. Pair with labs: Your genetic data is most useful when paired with current ApoB, fasting insulin, hsCRP, and hormone panels.

Key Takeaways

  • Genetics is a blueprint, not a destiny.
  • We translate raw data into actionable pathways.
  • Genetic data informs nutrients, medications, and screening timelines.
  • Privacy matters: your data lives in our HIPAA-compliant, encrypted system.

Scientific References

  1. Khera AV, et al. "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations." Nature Genetics. 2018.
  2. Hou L, et al. "Pharmacogenomic Testing in Clinical Practice." American Journal of Health-System Pharmacy. 2020.
  3. Manchanda R, et al. "Cost-effectiveness of population-based BRCA1, BRCA2 mutation testing." JAMA Oncology. 2018.
  4. Genin E, et al. "APOE and Alzheimer disease: a major gene with semi-dominant inheritance." Molecular Psychiatry. 2011.

Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.
Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Diagnostics

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Upload Results
Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all", the right plan must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash to determine if this approach is right for you, especially if you have chronic health conditions or are taking prescription medications.

Frequently Asked Questions

Common Questions

Yes, we can use your 23andMe raw data. We run it through clinical-grade analysis tools that look at variants beyond the consumer-facing 23andMe report. Raw data covers about 600,000 SNPs, which is enough for many pharmacogenomic and pathway questions, but it does not replace whole genome sequencing for rare-variant detection.
The difference between consumer and clinical genetic testing is depth, accuracy, and regulation. Consumer tests like 23andMe screen common variants and are FDA-cleared for limited uses. Clinical tests like Invitae or Color use validated CLIA labs and report on medically actionable variants with much higher confidence.
You do not need a referral to upload your data if you are already a Fishtown Medicine patient. Just attach the raw file in the Ultralight app. If you are not a member yet, schedule an intro visit and we will set up the secure upload during onboarding.
Your genetic data will not be shared with insurance from our office. Your records are protected by HIPAA. The federal GINA law also prohibits health insurers and employers from discriminating based on genetic information. Note that GINA does not cover life insurance, disability insurance, or long-term care insurance.
The review takes 7 to 10 days from upload to consult. We need time to process the raw data, cross-reference variants against current literature, and prepare the pathway summary. Rushing the review usually means missing the most useful insights.
Whole genome sequencing is better than 23andMe for depth and rare-variant detection. WGS covers 100 percent of your DNA. 23andMe covers about 0.02 percent. For most healthy adults, 23andMe data is enough to start. For complex family histories or unexplained symptoms, WGS is worth the cost.
Pharmacogenomic testing can tell you how your liver metabolizes specific drug families, including SSRIs, opioids, beta-blockers, statins, and PPIs. It can prevent years of trial and error with antidepressants and reduce the risk of overdose with codeine in ultra-rapid metabolizers.
The consult will tell you if your data shows known cancer-risk variants like BRCA1, BRCA2, or Lynch syndrome genes. Consumer raw data only flags some of these. We often recommend a confirmatory clinical panel (Invitae) before any major decision based on a 23andMe result alone.

Deep-Dive Questions

A polygenic risk score (PRS) combines many small genetic variants into one number that estimates your inherited risk for a specific disease. We use PRS for coronary artery disease, breast cancer, colon cancer, type 2 diabetes, and Alzheimer's, layered on top of family history and lifestyle to refine screening and prevention plans.
APOE genotype changes care because APOE4 carriers face higher risk of both Alzheimer's disease and cardiovascular disease, and their risk is amplified by saturated fat and alcohol. We are stricter about ApoB targets, sleep quality, exercise, and metabolic markers in APOE4 carriers, and we monitor cognition more carefully starting in midlife.
The role of MTHFR variants in real clinical care is more nuanced than the internet suggests. The C677T and A1298C variants slightly reduce folate metabolism efficiency. We do not "treat" MTHFR. We sometimes choose methylfolate over folic acid, especially in patients with low B12 or B9 status, and we monitor homocysteine.
We handle the COMT gene by using it as a context clue, not a label. Slow-COMT carriers often have higher dopamine baseline, more focus, and more sensitivity to caffeine and stress. We adjust supplements (more magnesium, fewer methyl donors) and conversation about caffeine timing rather than prescribing a specific protocol from a single gene.
The difference between BRCA testing and a polygenic breast cancer risk score is the type of risk. BRCA1 and BRCA2 are high-penetrance variants that confer 50 to 80 percent lifetime risk. Polygenic scores combine many small-effect variants and identify the 1 to 2 percent of women with elevated risk despite being BRCA-negative.
Pharmacogenomics affects SSRI selection because CYP2D6 and CYP2C19 status changes how fast you metabolize each drug. Poor metabolizers may build up high levels at standard doses. Ultra-rapid metabolizers may never reach therapeutic levels. We use the data to choose the right drug at the right dose on the first try.
GINA is the Genetic Information Nondiscrimination Act of 2008. It protects you from discrimination by health insurers and employers based on genetic information. It does not protect you in the markets for life insurance, disability insurance, or long-term care insurance. We discuss this trade-off before any deep genetic testing.
We interpret a variant of uncertain significance (VUS) by usually doing nothing dramatic. A VUS is a genetic change with no clear medical meaning yet. We document it, follow updates from clinical databases like ClinVar, and re-evaluate periodically. We never let a VUS drive surgery or aggressive treatment.
Lifestyle change can substantially override a high-risk genetic profile in many cases. For coronary artery disease, exercise, diet, and lipid lowering can reduce risk by more than 50 percent even in high-PRS patients. For BRCA1, lifestyle helps but does not replace targeted screening or risk-reducing surgery decisions.
Fishtown Medicine handles direct-to-consumer pharmacogenomic kits cautiously. Some, like GeneSight, are FDA-cleared for psychiatric medications. Others have variable evidence. We treat consumer reports as starting points, confirm with clinical-grade testing when needed, and make decisions based on the totality of clinical context.
Polygenic embryo screening is an emerging area where IVF embryos are scored for adult disease risk and intelligence proxies. We do not currently use it. The science is early, the ethics are complicated, and the predictive power for any individual embryo is small. We will revisit when the data is stronger.
Fishtown Medicine still emphasizes family history alongside genetics because family history captures shared environment, lifestyle, and genetic variants we have not yet sequenced. A patient whose father and grandfather both died of heart attacks at 50 has meaningful risk even when the 23andMe report looks clean.

Still have a question?

He answers personally. Usually within a few hours.

Related Intelligence

Managing Labs and Imaging with Ease

Managing Labs and Imaging with Ease

Confused about where to go for labs or scans? Learn how Fishtown Medicine helps you navigate local Philadelphia diagnostics while maximizing your insurance coverage.

Read Deep Dive
Boutique Scans & Whole-Body MRI: A Clinical Review

Boutique Scans & Whole-Body MRI: A Clinical Review

Is a full-body MRI worth it? Learn the pros and cons of boutique scans like Prenuvo and PET-CTs, and how Fishtown Medicine chooses the right cancer detection strategy.

Read Deep Dive
Longevity Strategies | Fishtown Medicine

Longevity Strategies | Fishtown Medicine

Strategies to extend your healthspan and optimize lifespan in Philadelphia.

Read Deep Dive

Talk it through with Dr. Ash.

If anything you read here raised a question, this is a free 20-minute Warm Invitation Call. Pick a time and we’ll work through it together.

HSA/FSA eligible
No initiation or cancellation fees
No copays

Loading scheduler...

Having trouble with the scheduler? Book directly on Dr. Ash’s calendar

FishtownFish wrapped around the rod of AsclepiusMedicine
Philadelphia Primary Care
2418 E York St, Philadelphia, PA 19125Home visits in Greater Philadelphia

Serving Fishtown · Art Museum · Bella Vista · Callowhill · Center City · Center City West · Chestnut Hill · East Kensington · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Northern Liberties · Old City · Olde Richmond · Poplar · Port Richmond · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • TRT Therapy
  • TRT Safety
  • TRT vs Enclomiphene
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical Independence